|
| Status |
Public on Jul 23, 2021 |
| Title |
IL-13 neutralization effect on COVID-19 severity |
| Organism |
Mus musculus |
| Experiment type |
Expression profiling by high throughput sequencing
|
| Summary |
We investigated the effect of IL-13 neutralization on COVID-19 disease progression in mice.
|
| |
|
| Overall design |
We analyzed the bulk lung tissue transcriptomes in Covid19 infected mice treated with anti-IL-13 or isotype (IgG) control antibodies and uninfected mice as an additional control group. 8-16 week-old male Tg(K18-hACE2) 2Prlmn (Jackson Laboratories) mice were challenged with 5000 plaque forming units (PFUs) of SARS-CoV-2 Hong Kong/VM20001061/2020 (BEI 14 Resources) in 50 μL by an intranasal route under 100 μL ketamine/xylazine sedation. Mice were given 150 μg of anti-IL-13(Thermofisher, clone eBio1316H; cat # 16-7135-85) or an isotype matched control IgG (Thermofisher, clone eBRG1; cat # 16-4301-85) administered on day 0, 2, and 4 pi. Mice were euthanzied at 5 days post-infection and lung tissue was resected for RNA-sequencing analysis.
|
| |
|
| Contributor(s) |
Marie C, Jan N |
| Citation(s) |
34185704 |
| NIH grant(s) |
| Grant ID |
Grant title |
Affiliation |
Name |
| R01 AI148518 |
Role of Host Protein Kinase C in Cryptosporidiosis |
UNIVERSITY OF VIRGINIA CHARLOTTESVILLE |
Chelsea S. Marie |
|
| |
| Submission date |
Jul 21, 2021 |
| Last update date |
Jul 23, 2021 |
| Contact name |
Chelsea Marie |
| E-mail(s) |
csm8r@virginia.edu
|
| Phone |
4349246511
|
| Organization name |
University of Virginia School of Medicine
|
| Department |
Medicine
|
| Lab |
Marie Lab
|
| Street address |
345 Crispell Drive
|
| City |
Charlottesville |
| State/province |
VA |
| ZIP/Postal code |
22903 |
| Country |
USA |
| |
|
| Platforms (1) |
| GPL19057 |
Illumina NextSeq 500 (Mus musculus) |
|
| Samples (15)
|
| GSM5464747 |
CM_01: Covid 19 infected treated with IgG-rep 1 |
| GSM5464748 |
CM_02: Covid 19 infected treated with IgG-rep 2 |
| GSM5464749 |
CM_03: Covid 19 infected treated with IgG-rep 3 |
| GSM5464750 |
CM_04: Covid 19 infected treated with IgG-rep 4 |
| GSM5464751 |
CM_05: Covid 19 infected treated with IgG-rep 5 |
| GSM5464752 |
CM_06: Covid 19 infected treated with anti-IL13- rep 1 |
| GSM5464753 |
CM_07: Covid 19 infected treated with anti-IL13- rep 2 |
| GSM5464754 |
CM_08: Covid 19 infected treated with anti-IL13- rep 3 |
| GSM5464755 |
CM_09: Covid 19 infected treated with anti-IL13- rep 4 |
| GSM5464756 |
CM_10: Covid 19 infected treated with anti-IL13- rep 5 |
| GSM5464757 |
CM_11: uninfected rep 1 |
| GSM5464758 |
CM_12: uninfected rep 2 |
| GSM5464759 |
CM_13: uninfected rep 3 |
| GSM5464760 |
CM_14: uninfected rep 4 |
| GSM5464761 |
CM_15: uninfected rep 5 |
|
| Relations |
| BioProject |
PRJNA748702 |
| SRA |
SRP329285 |
Less...
More...